Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Cash from Investing Activities: 2013-2024

Historic Cash from Investing Activities for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Dec 2024 value amounting to -$228.7 million.

  • Viridian Therapeutics, Inc.\DE's Cash from Investing Activities rose 248.91% to $126.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $238.9 million, marking a year-over-year increase of 171.23%. This contributed to the annual value of -$228.7 million for FY2024, which is 142.60% down from last year.
  • According to the latest figures from FY2024, Viridian Therapeutics, Inc.\DE's Cash from Investing Activities is -$228.7 million, which was down 142.60% from -$94.3 million recorded in FY2023.
  • Viridian Therapeutics, Inc.\DE's Cash from Investing Activities' 5-year high stood at -$50.5 million during FY2020, with a 5-year trough of -$228.7 million in FY2024.
  • Over the past 3 years, Viridian Therapeutics, Inc.\DE's median Cash from Investing Activities value was -$115.1 million (recorded in 2022), while the average stood at -$146.0 million.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Cash from Investing Activities crashed by 278.85% in 2020 and then increased by 18.13% in 2023.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Cash from Investing Activities (Yearly) stood at -$50.5 million in 2020, then plummeted by 47.17% to -$74.3 million in 2021, then tumbled by 54.96% to -$115.1 million in 2022, then increased by 18.13% to -$94.3 million in 2023, then plummeted by 142.60% to -$228.7 million in 2024.